With research comes progress. The Registry is leading research initiatives that can be the motivation for transforming the way PPB/DICER1 is detected and treated.
Define optimal therapy for PPB, Sertoli-Leydig cell tumor and other DICER1-related cancers
Validate testing and surveillance guidelines for children and adults with germline DICER1 variations
Develop new ways to diagnose and follow children with DICER1-related cancers
Discover new therapies for DICER1-related cancers
Pathologists are invited to connect with the Registry regarding free central pathology review (no charge to institution or patient/family).
Left over tumor tissue (tumor tissue removed for a clinical reason but not needed for clinical care) is studied for several purposes:
We encourage all treating physicians and families to consider participating in the Registry to allow sharing of clinical data and tumor tissue.